Literature DB >> 33764481

Deciphering Tumor Heterogeneity in Hepatocellular Carcinoma (HCC)-Multi-Omic and Singulomic Approaches.

Renumathy Dhanasekaran1.   

Abstract

Tumor heterogeneity, a key hallmark of hepatocellular carcinomas (HCCs), poses a significant challenge to developing effective therapies or predicting clinical outcomes in HCC. Recent advances in next-generation sequencing-based multi-omic and single cell analysis technologies have enabled us to develop high-resolution atlases of tumors and pull back the curtain on tumor heterogeneity. By combining multiregion targeting sampling strategies with deep sequencing of the genome, transcriptome, epigenome, and proteome, several studies have revealed novel mechanistic insights into tumor initiation and progression in HCC. Advances in multiparametric immune cell profiling have facilitated a deeper dive into the biological complexity of HCC, which is crucial in this era of immunotherapy. Moreover, studies using liquid biopsy have demonstrated their potential to circumvent the need for tissue sampling to investigate heterogeneity. In this review, we discuss how multi-omic and single-cell sequencing technologies have advanced our understanding of tumor heterogeneity in HCC. Thieme. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33764481      PMCID: PMC8136683          DOI: 10.1055/s-0040-1722261

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  59 in total

1.  Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma.

Authors:  Ao Huang; Xin Zhao; Xin-Rong Yang; Fu-Qiang Li; Xin-Lan Zhou; Kui Wu; Xin Zhang; Qi-Man Sun; Ya Cao; Hong-Mei Zhu; Xiang-Dong Wang; Huan-Ming Yang; Jian Wang; Zhao-You Tang; Yong Hou; Jia Fan; Jian Zhou
Journal:  J Hepatol       Date:  2017-03-18       Impact factor: 25.083

2.  Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification.

Authors:  Bo Hu; Hong Li; Wei Guo; Yun-Fan Sun; Xin Zhang; Wei-Guo Tang; Liu-Xiao Yang; Yang Xu; Xiao-Yan Tang; Guo-Hui Ding; Shuang-Jian Qiu; Jian Zhou; Yi-Xue Li; Jia Fan; Xin-Rong Yang
Journal:  Int J Cancer       Date:  2019-08-09       Impact factor: 7.396

Review 3.  Role of Telomeres and Telomerase in Aging and Cancer.

Authors:  Jerry W Shay
Journal:  Cancer Discov       Date:  2016-03-30       Impact factor: 39.397

4.  Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification.

Authors:  Yutaka Kurebayashi; Hidenori Ojima; Hanako Tsujikawa; Naoto Kubota; Junki Maehara; Yuta Abe; Minoru Kitago; Masahiro Shinoda; Yuko Kitagawa; Michiie Sakamoto
Journal:  Hepatology       Date:  2018-07-25       Impact factor: 17.425

5.  Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution.

Authors:  Shaoping Ling; Zheng Hu; Zuyu Yang; Fang Yang; Yawei Li; Pei Lin; Ke Chen; Lili Dong; Lihua Cao; Yong Tao; Lingtong Hao; Qingjian Chen; Qiang Gong; Dafei Wu; Wenjie Li; Wenming Zhao; Xiuyun Tian; Chunyi Hao; Eric A Hungate; Daniel V T Catenacci; Richard R Hudson; Wen-Hsiung Li; Xuemei Lu; Chung-I Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-11       Impact factor: 11.205

6.  Identification of driver genes in hepatocellular carcinoma by exome sequencing.

Authors:  Sean P Cleary; William R Jeck; Xiaobei Zhao; Kui Chen; Sara R Selitsky; Gleb L Savich; Ting-Xu Tan; Michael C Wu; Gad Getz; Michael S Lawrence; Joel S Parker; Jinyu Li; Scott Powers; Hyeja Kim; Sandra Fischer; Maha Guindi; Anand Ghanekar; Derek Y Chiang
Journal:  Hepatology       Date:  2013-09-24       Impact factor: 17.425

Review 7.  Molecular therapies for HCC: Looking outside the box.

Authors:  Sandrine Faivre; Lorenza Rimassa; Richard S Finn
Journal:  J Hepatol       Date:  2020-02       Impact factor: 25.083

8.  Hepatocellular Carcinoma Xenografts Established From Needle Biopsies Preserve the Characteristics of the Originating Tumors.

Authors:  Tanja Blumer; Isabel Fofana; Matthias S Matter; Xueya Wang; Hesam Montazeri; Diego Calabrese; Mairene Coto-Llerena; Tujana Boldanova; Sandro Nuciforo; Venkatesh Kancherla; Luigi Tornillo; Salvatore Piscuoglio; Stefan Wieland; Luigi M Terracciano; Charlotte K Y Ng; Markus H Heim
Journal:  Hepatol Commun       Date:  2019-05-06

9.  Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity.

Authors:  Ao Huang; Xin Zhang; Shao-Lai Zhou; Ya Cao; Xiao-Wu Huang; Jia Fan; Xin-Rong Yang; Jian Zhou
Journal:  J Cancer       Date:  2016-09-13       Impact factor: 4.207

Review 10.  T cell clonality assessment: past, present and future.

Authors:  Etienne Mahe; Tevor Pugh; Suzanne Kamel-Reid
Journal:  J Clin Pathol       Date:  2017-10-21       Impact factor: 3.411

View more
  5 in total

1.  Treacherous apoptosis-Cancer cells sacrifice themselves at the altar of heterogeneity.

Authors:  Renumathy Dhanasekaran
Journal:  Hepatology       Date:  2022-03-14       Impact factor: 17.298

2.  A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.

Authors:  Stephen L Chan; Martin Schuler; Yoon-Koo Kang; Chia-Jui Yen; Julien Edeline; Su Pin Choo; Chia-Chi Lin; Takuji Okusaka; Karl-Heinz Weiss; Teresa Macarulla; Stéphane Cattan; Jean-Frederic Blanc; Kyung-Hun Lee; Michela Maur; Shubham Pant; Masatoshi Kudo; Eric Assenat; Andrew X Zhu; Thomas Yau; Ho Yeong Lim; Jordi Bruix; Andreas Geier; Carmen Guillén-Ponce; Angelica Fasolo; Richard S Finn; Jia Fan; Arndt Vogel; Shukui Qin; Markus Riester; Vasiliki Katsanou; Monica Chaudhari; Tomoyuki Kakizume; Yi Gu; Diana Graus Porta; Andrea Myers; Jean-Pierre Delord
Journal:  J Exp Clin Cancer Res       Date:  2022-06-02

3.  Functional stratification of cancer drugs through integrated network similarity.

Authors:  Seyma Unsal-Beyge; Nurcan Tuncbag
Journal:  NPJ Syst Biol Appl       Date:  2022-04-19

4.  CpG Site-Specific Methylation-Modulated Divergent Expression of PRSS3 Transcript Variants Facilitates Nongenetic Intratumor Heterogeneity in Human Hepatocellular Carcinoma.

Authors:  Shuye Lin; Hanli Xu; Mengdi Pang; Xiaomeng Zhou; Yuanming Pan; Lishu Zhang; Xin Guan; Xiaoyue Wang; Bonan Lin; Rongmeng Tian; Keqiang Chen; Xiaochen Zhang; Zijiang Yang; Fengmin Ji; Yingying Huang; Wu Wei; Wanghua Gong; Jianke Ren; Ji Ming Wang; Mingzhou Guo; Jiaqiang Huang
Journal:  Front Oncol       Date:  2022-04-11       Impact factor: 5.738

5.  The Association between Immune Subgroups and Gene Modules for the Clinical, Cellular, and Molecular Characteristic of Hepatocellular Carcinoma.

Authors:  Wenbiao Chen; Peng Zhu; Huixuan Xu; Xianliang Hou; Changchun Guo
Journal:  J Oncol       Date:  2022-08-31       Impact factor: 4.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.